Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT1021 in advanced solid tumors
NCT03364400Phase 1Unknown
- Sponsor
- Vigeo Therapeutics
- Start
- Nov 2017
- Primary completion
- Jan 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VT1021 in solid tumor, ovarian cancer, pancreatic cancer (PC) and 2 more, sponsored by Vigeo Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 4 weeks and Safety and Tolerability at 4 weeks. Status: unknown.
02
Drugs
VT1021
03
Conditions
solid tumorovarian cancerpancreatic cancer (PC)triple-negative breast cancer (TNBC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03364400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364400.